Company intelligence
Nucleic Acid Therapeutics Initiative (NATi)
Innovating for Better RNA Medicines
About Nucleic Acid Therapeutics Initiative (NATi)
The Nucleic Acid Therapeutics Initiative (NATi) is a national platform that aims to build Singapore into a regional hub for nucleic acid therapeutics (NAT) research, clinical translation, and commercialisation. NATi harnesses the potential of nucleic acids to treat diseases using RNA molecules. This initiative bolsters strategic partnerships and propels healthcare innovations, benefitting Singapore and Singaporeans.
Verified activity
Signals from Nucleic Acid Therapeutics Initiative (NATi)
4 published signals
Presence & Recognition
Nucleic Acid Therapeutics Initiative (NATi) Executive Director Dr Mohamed ElSayed Ph.D. will be participating as a panelist at RNA World 2026 in Shanghai, China.
Reported by Nucleic Acid Therapeutics Initiative (NATi)
Presence & Recognition
Nucleic Acid Therapeutics Initiative (NATi) participated in the RNA Leaders APAC 2026 event, attending sessions and meeting with researchers, biotech companies, technology providers, investors, and ecosystem partners.
Reported by Nucleic Acid Therapeutics Initiative (NATi)
Presence & Recognition
Nucleic Acid Therapeutics Initiative (NATi) participated in the RNA Leaders APAC 2026 event, attending sessions and meeting with researchers, biotech companies, technology providers, investors, and ecosystem partners.
Reported by Nucleic Acid Therapeutics Initiative (NATi)
Presence & Recognition
Nucleic Acid Therapeutics Initiative (NATi) Executive Director Mohamed ElSayed delivered an opening address at the RNA Leaders APAC 2026 event in Singapore.
Reported by Nucleic Acid Therapeutics Initiative (NATi)